# AVEO Pharmaceuticals Inc. (AVEO)

Source: https://www.quantisnow.com/company/AVEO
Generated: 2026-11-09T12:59:56.392Z

- Ticker: AVEO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2010
- Website: aveooncology.com

## About

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

## Latest AVEO news and filings

- 2024-03-22 22:14 UTC [2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers](https://www.quantisnow.com/insight/2024-entrepreneurship-summit-presented-by-the-harvard-undergraduate-venture-capital-5364629)
- 2023-01-30 21:07 UTC [SEC Form 15-12G filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-aveo-pharmaceuticals-inc-3973690)
- 2023-01-24 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-aveo-pharmaceuticals-inc-3943120)
- 2023-01-24 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-aveo-pharmaceuticals-inc-3943118)
- 2023-01-24 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-aveo-pharmaceuticals-inc-3943107)
- 2023-01-19 22:19 UTC [SEC Form 4] [SEC Form 4: Bate Kenneth returned $5,625 worth of shares to the company (375 units at $15.00), decreasing direct ownership by 50% to 375 units (tax liability)](https://www.quantisnow.com/insight/sec-form-4-bate-kenneth-returned-5625-worth-of-shares-3931357)
- 2023-01-19 22:16 UTC [SEC Form 4] [SEC Form 4: Evnin Anthony B returned $627,615 worth of shares to the company (41,841 units at $15.00), closing all direct ownership in the company to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-evnin-anthony-b-returned-627615-worth-of-3931324)
- 2023-01-19 22:16 UTC [SEC Form 4] [SEC Form 4 filed by Ledell Jebediah (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-filed-by-ledell-jebediah-tax-withholding-3931322)
- 2023-01-19 22:15 UTC [SEC Form 4] [SEC Form 4: Ferraresso Michael returned $245,175 worth of shares to the company (16,345 units at $15.00), closing all direct ownership in the company to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-ferraresso-michael-returned-245175-worth-of-shares-3931315)
- 2023-01-19 22:15 UTC [SEC Form 4] [SEC Form 4 filed by Epperly Corinne to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-filed-by-epperly-corinne-to-satisfy-tax-3931312)
- 2023-01-19 22:14 UTC [SEC Form 4] [SEC Form 4 filed by Cullen Kevin Joseph (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-filed-by-cullen-kevin-joseph-for-withholding-3931301)
- 2023-01-19 22:13 UTC [SEC Form 4] [SEC Form 4 filed by Spring Scarlett to satisfy tax liability](https://www.quantisnow.com/insight/sec-form-4-filed-by-spring-scarlett-to-satisfy-tax-3931298)
- 2023-01-19 22:12 UTC [SEC Form 4] [SEC Form 4 filed by Mayes, Gregory T. (withholding obligation)](https://www.quantisnow.com/insight/sec-form-4-filed-by-mayes-gregory-t-withholding-obligation-3931286)
- 2023-01-19 22:11 UTC [SEC Form 4] [SEC Form 4: Bailey Michael P returned $4,997,505 worth of shares to the company (333,167 units at $15.00), closing all direct ownership in the company (for withholding tax)](https://www.quantisnow.com/insight/sec-form-4-bailey-michael-p-returned-4997505-worth-of-3931280)
- 2023-01-19 22:11 UTC [SEC Form 4] [SEC Form 4 filed by Lucera Erick to satisfy withholding obligation](https://www.quantisnow.com/insight/sec-form-4-filed-by-lucera-erick-to-satisfy-withholding-3931277)
- 2023-01-19 21:47 UTC [SEC Form POS AM filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-aveo-pharmaceuticals-inc-3931029)
- 2023-01-19 21:46 UTC [SEC Form POS AM filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-aveo-pharmaceuticals-inc-3931019)
- 2023-01-19 21:45 UTC [SEC Form POS AM filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-aveo-pharmaceuticals-inc-3931015)
- 2023-01-19 21:43 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930996)
- 2023-01-19 21:43 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930989)
- 2023-01-19 21:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930981)
- 2023-01-19 21:41 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930974)
- 2023-01-19 21:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930965)
- 2023-01-19 21:39 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930963)
- 2023-01-19 21:38 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-aveo-pharmaceuticals-inc-3930944)
- 2023-01-19 21:35 UTC [SEC Form 8-K] [AVEO Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/aveo-pharmaceuticals-inc-filed-sec-form-8-k-termination-of-a-3930922)
- 2023-01-19 21:35 UTC [LG Chem Completes Acquisition of AVEO Oncology](https://www.quantisnow.com/insight/lg-chem-completes-acquisition-of-aveo-oncology-3930913)
- 2023-01-18 13:54 UTC [Market Chatter] [Aveo Oncology Form 8 Filing, Closing Of The Merger Is Expected To Occur On January 19, 2023](https://www.quantisnow.com/insight/aveo-oncology-form-8-filing-closing-of-the-merger-is-3922164)
- 2023-01-18 13:53 UTC [Market Chatter] [On Jan 17, Aveo Oncology's Lg Chem Received Written Notice From CFIUS That There Were No Unresolved National Security Concerns Regarding Transaction;  All Required Regulatory Approvals To Complete Merger Have Now Been Received](https://www.quantisnow.com/insight/on-jan-17-aveo-oncologys-lg-chem-received-written-notice-3922158)
- 2023-01-18 13:40 UTC [SEC Form 8-K] [AVEO Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/aveo-pharmaceuticals-inc-filed-sec-form-8-k-other-events-3922092)
- 2023-01-06 05:40 UTC [Market Chatter] [AVEO Oncology Stockholders Approve Acquisition By LG Chem;  AVEO Stockholders Will Receive $15.00 Per Share In Cash Upon The Closing Of The Transaction](https://www.quantisnow.com/insight/aveo-oncology-stockholders-approve-acquisition-by-lg-chem-aveo-stockholders-3881375)
- 2023-01-06 00:35 UTC [AVEO Oncology Stockholders Approve Acquisition by LG Chem](https://www.quantisnow.com/insight/aveo-oncology-stockholders-approve-acquisition-by-lg-chem-3881012)
- 2023-01-05 21:58 UTC [SEC Form 8-K] [AVEO Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/aveo-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-3880088)
- 2023-01-03 21:05 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aveo-pharmaceuticals-inc-3864744)
- 2023-01-03 13:16 UTC [AVEO Oncology Reminds Stockholders to Vote "FOR" All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders](https://www.quantisnow.com/insight/aveo-oncology-reminds-stockholders-to-vote-for-all-cash-transaction-with-3861859)
- 2022-12-23 21:01 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aveo-pharmaceuticals-inc-3842452)
- 2022-12-22 21:46 UTC [SEC Form 4] [SEC Form 4: Bailey Michael P exercised 276,746 shares at a strike of $4.51, increasing direct ownership by 503% to 340,167 units](https://www.quantisnow.com/insight/sec-form-4-bailey-michael-p-exercised-276746-shares-at-3839293)
- 2022-12-20 21:02 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aveo-pharmaceuticals-inc-3828882)
- 2022-12-02 14:10 UTC [Market Chatter] [Aveo Oncology Says Effective As Of 11:59 p.m. Eastern Time On December 1, 2022, Waiting Period Under HSR Act Expired With Respect To LG Chem Merger](https://www.quantisnow.com/insight/aveo-oncology-says-effective-as-of-1159-pm-eastern-time-3760398)
- 2022-12-02 14:07 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by AVEO Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-aveo-pharmaceuticals-inc-3760380)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AVEO
- Earnings history: https://www.quantisnow.com/earnings/AVEO
- Dividend history: https://www.quantisnow.com/dividends/AVEO
- Insider transactions: https://www.quantisnow.com/insiders/AVEO
- Options chain: https://www.quantisnow.com/options/AVEO
- SEC 8-K filings only: https://www.quantisnow.com/company/AVEO/8-k
- RSS and alerts for AVEO: https://www.quantisnow.com/docs/rss-feeds.md